Actively Recruiting
A Pilot Investigation to Determine the Utility of Liquid Biopsies and Tumor Molecular Profiling in Predicting Recurrence in Endometrial Cancer
Led by M.D. Anderson Cancer Center · Updated on 2026-05-06
1000
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are studying how well liquid biopsies work as a less invasive alternative to traditional methods for detecting cancer cells in patients with endometrial cancer. This observational study aims to compare genetic changes found in blood samples with those in tumor tissue, helping doctors understand how cancer cells may change during treatment and how these changes relate to cancer recurrence. Participants provide blood samples for liquid biopsy at several points: before surgery, after hysterectomy but before chemotherapy, and after the last chemotherapy cycle. Tissue samples are also collected during surgery, and Pap smears may be performed before and after hysterectomy. The study compares gene variant frequencies in circulating cell-free DNA to tumor sequencing and explores immune and RNA profiles of different endometrial cancer subtypes. During the study, patients undergo blood draws, tissue collection, and possibly Pap smears. Researchers analyze these samples to track gene mutations and immune profiles, aiming to estimate cancer progression time and recurrence risk. The main outcome measured is the proportion of circulating cell-free DNA mutations over about one year. The study involves informed consent and regular sample collection throughout the treatment course.
CONDITIONS
Brief Title
Determine the Utility of Liquid Biopsies and Tumor Molecular Profiling in Predicting Recurrence in Endometrial Cancers
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Women age 18 years and older
- Histologic diagnosis of endometrial cancer
- Candidate for primary surgical treatment or has recently had prior primary surgery
- Willing and able to provide informed consent
You will not qualify if you...
- Received prior chemotherapy or radiation therapy for endometrial cancer
- Patients with prior primary surgery must not have received chemotherapy or radiation at enrollment
- Patients with history of other cancers may be excluded unless determined low risk for recurrence or metastasis by the principal investigator
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 1 week around surgery
Participants undergo collection of blood samples for liquid biopsy and Pap smear before hysterectomy, as well as tissue sampling during hysterectomy.
3 visits (pre-treatment consultation, surgery, post-surgery)
Duration - Up to 1 year
Participants undergo blood sample collection for liquid biopsy after hysterectomy but before chemotherapy, after last chemotherapy cycle, and may have Pap smears before and after hysterectomy for monitoring recurrence and progression.
3 to 4 visits depending on treatment schedule
Trial Site Locations
Total: 1 location
1
M D Anderson Cancer Center
Houston, Texas, United States, 77030
Actively Recruiting
Research Team
P
Pamela T Soliman, MD
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here